HUMA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.132

-17.71%

-0.120

-142.86%

-0.115

-52.08%

Estimates Revision

The market is revising Downward the revenue expectations for Humacyte, Inc. (HUMA) for FY2025, with the revenue forecasts being adjusted by -24.08% over the past three months. During the same period, the stock price has changed by -25.00%.

Revenue Estimates for FY2025

Revise Downward

-24.08%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-20.88%

In Past 3 Month

Stock Price

Go Down

-25.00%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.40 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.40

High

11.00

Current: 0.000

Low

3.00

Averages

5.40

High

11.00

Benchmark

Bruce Jackson

Buy

downgrade

$14 -> $11

2025-11-13

Reason

Benchmark

Bruce Jackson

Price Target

$14 -> $11

2025-11-13

downgrade

Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Humacyte to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte's new shares for the target drop but believes the company's customer base continues to build.

Barclays

Matt Miksic

Overweight

initiated

$3.50

2025-08-27

Reason

Barclays

Matt Miksic

Price Target

$3.50

2025-08-27

initiated

Overweight

Reason

Barclays analyst Matt Miksic initiated coverage of Humacyte with an Overweight rating and $3.50 price target. The company is in the early stages of launching Symvess in vascular trauma, which is the first of four initial indications for its acellular tissue engineered vessel, the analyst tells investors in a research note. Barclays says the initial indication addresses significant challenges and costs associated with the care of patients suffering from vascular trauma. It sees potential sales of over $600M.

H.C. Wainwright

Buy

downgrade

$4 -> $3

2025-08-12

Reason

H.C. Wainwright

Price Target

$4 -> $3

2025-08-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Humacyte to $3 from $4 and keeps a Buy rating on the shares. The firm says the company's July sales growth suggests potential momentum.

TD Cowen

Buy

downgrade

2025-08-12

Reason

TD Cowen

Price Target

2025-08-12

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Humacyte to $3.50 from $5 and keeps a Buy rating on the shares. The firm said the Symvess launch continues to advance with 13 hospital VAC approvals now in hand up from 5 in 1Q'25. Cowen said they are encouraged by this recent improvement in commercial traction and expect sequential revenue growth throughout 2H'25 and 2026.

Benchmark

analyst

Buy

downgrade

$17 -> $14

2025-05-14

Reason

Benchmark

analyst

Price Target

$17 -> $14

2025-05-14

downgrade

Buy

Reason

Benchmark lowered the firm's price target on Humacyte to $14 from $17 and keeps a Buy rating on the shares. Humacyte launched Symvess in February and generated its first commercial product revenue during Q1, notes the analyst, who believes the company is poised to gain significant share for surgical procedures requiring vascular grafts and notes that the new product pipeline continues to move forward.

H.C. Wainwright

Buy

initiated

2025-05-14

Reason

H.C. Wainwright

Price Target

2025-05-14

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Humacyte with a Buy rating and $4 price target. Humacyte's lead product, Symvess, was approved as a vascular conduit in extremity vascular trauma at the end of 2024 and management initiated U.S. commercialization of the product in February, notes the analyst, who is "encouraged" that the product achieved approximately $0.5M in the first two months of launch. The company has completed enrollment in the Phase 3 V007 study evaluating the acellular tissue engineered vessel for arteriovenous access for hemodialysis and in order to "monetize Symvess to the fullest extent," the company is conducting two additional Phase 2 studies, V002 and V004, evaluating the ATEV in peripheral artery disease, the analyst added.

Valuation Metrics

The current forward P/E ratio for Humacyte Inc (HUMA.O) is -2.08, compared to its 5-year average forward P/E of -5.87. For a more detailed relative valuation and DCF analysis to assess Humacyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.87

Current PE

-2.08

Overvalued PE

-1.63

Undervalued PE

-10.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.23

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.69

Undervalued EV/EBITDA

-8.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

740.29

Current PS

9.86

Overvalued PS

2075.08

Undervalued PS

-594.51

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HUMA News & Events

Events Timeline

No data

News

6.0

2025-11-21Benzinga

BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact

6.0

2025-11-20Benzinga

D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact

4.0

2025-11-13Benzinga

Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11

People Also Watch

Frequently Asked Questions

What is Humacyte Inc (HUMA) stock price today?

The current price of HUMA is 1.17 USD — it has increased 0 % in the last trading day.

What is Humacyte Inc (HUMA)'s business?

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

What is the price predicton of HUMA Stock?

What is Humacyte Inc (HUMA)'s revenue for the last quarter?

Humacyte Inc revenue for the last quarter amounts to 753.00K USD, decreased % YoY.

What is Humacyte Inc (HUMA)'s earnings per share (EPS) for the last quarter?

Humacyte Inc. EPS for the last quarter amounts to -0.11 USD, decreased -66.67 % YoY.

What changes have occurred in the market's expectations for Humacyte Inc (HUMA)'s fundamentals?

How many employees does Humacyte Inc (HUMA). have?

Humacyte Inc (HUMA) has 218 emplpoyees as of January 10 2026.

What is Humacyte Inc (HUMA) market cap?

Today HUMA has the market capitalization of 225.81M USD.